Nautilus Biotechnology Q3 revenue beats
NAUT•Nautilus Biotechnology reported third-quarter revenue of $234,000, above the $206,250 analyst consensus, while its net loss widened to $15.64 million. Operating expenses rose 10% to $16.95 million.
1. Revenue and costs
Third-quarter revenue was mainly from a grant awarded by The Michael J. Fox Foundation and service sales under the Iterative Mapping Early Access Program. The company reported a loss per share of $0.12; operating expenses increased 10% because of higher lab, professional services and personnel costs.
2. Platform outlook
Nautilus expects its Voyager platform instrument to be available in mid-2027 and plans to deliver twenty proteoform assays through mid-2028. It expects up to $6 million in SEEDS consortium funding for Voyager platform deployment.
3. Research progress
The company co-published peer-reviewed research demonstrating potential for new biomarkers and drug targets.
